Shares in Biogen (NSDQ:BIIB) fell this week after the biopharmaceutical company met expectations on Wall Street with its 4th quarter financial results, but pegged its full-year revenue forecast lower than analysts expected.
The Cambridge, Mass.-based company posted profits of $649.2 million, or $2.99 per share, on sales of $2.87 billion for the 3 months ended Dec. 31, for bottom-line loss of -21.9% on sales growth of 1.1% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Biogen beats Q4 earnings, misses on full-year rev forecast appeared first on MassDevice.
from MassDevice http://ift.tt/2jB3WWH
Cap comentari:
Publica un comentari a l'entrada